Korea's first homegrown GLP-1 obesity drug, efpeglenatide, comes in about 25% below Wegovy and 40% below Mounjaro for its first four weeks.
Recap by typeshit. Full story at 파이낸셜뉴스.
MedPage Today
She's screened for diabetes at a BMI of 23 but denied a GLP-1 until 30. She argues insurers should use ethnicity-adjusted thresholds that guidelines already publish.
Pharmacist Paige notes the second round of Medicare drug price negotiation starts January 1, 2027, with the semaglutide family on the list.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
Bloomberg reports that employer coverage of GLP-1 weight loss drugs is shrinking, leaving fewer US workers with access through their health plans.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Loading…